Keren Cohen

Keren Cohen has a diverse work experience in the biopharmaceutical industry. Keren started their career as a Teaching Assistant at Tel Aviv University from 2008 to 2013. Keren then joined Quiet Therapeutics in 2013 as a Researcher and later became the Project Leader for Formulation and Process Development. At Quiet Therapeutics, they were responsible for overseeing and managing the formulation and process science for the company's drug platform. In 2017, Keren joined Aummune as the Director of Preclinical Studies, where they led internal preclinical trials and defined strategies for the early development of individualized therapeutics technology. In 2019, they moved to Ayala Pharmaceuticals as a Project Lead, working as a scientist in the R&D team and leading projects for the development of gamma-secretase inhibitors. Currently, they hold the position of Preclinical Science & Discovery Manager at UroGen Pharma since 2020. Overall, Keren has gained extensive experience in project management, preclinical research, and drug development throughout their career.

Keren Cohen completed their Bachelor of Science (B.Sc.) degree in Life Sciences from Tel Aviv University between 2005 and 2008. Following their undergraduate studies, Keren pursued a Doctor of Philosophy (Ph.D.) degree in Cell Research and Immunology at Tel Aviv University. The specific start and end years for their Ph.D. program are not provided.